Clinic-pathologic characteristics of autoimmune diseases combined with non-Hodgkin's lymphoma.
- Author:
Ya-Ping YU
1
;
Hai-Ning LIU
;
Yong-Ping ZHAI
;
Ping SHI
;
Ping SONG
;
Feng LI
;
Xiao-Gang ZHOU
;
Yu-Mei TANG
Author Information
1. Department of Hematology, Nanjing General Hospital of Chinese PLA Nanjing Military Area, Nanjing 210002, Jiangsu Province, China. yuyapingnj@sina.com
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Autoimmune Diseases;
diagnosis;
pathology;
therapy;
Female;
Humans;
Lymphoma, Non-Hodgkin;
diagnosis;
pathology;
therapy;
Male;
Middle Aged;
Retrospective Studies
- From:
Journal of Experimental Hematology
2011;19(1):124-129
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the clinical characteristics and treatment of patients with autoimmune disease combined with non-Hodgkin lymphoma (NHL). The clinical characteristics and pathologic patterns of 6 patients with NHL who concurrently suffered from autoimmune diseases were analysed retrospectively from aspects of clinical course, pathologic features, and therapy. Treatment outcomes for autoimmune diseases and NHL were observed. The results showed that 6 patients included 4 females and 2 males, range in age from 28 to 65 years with a median age of 56 years. The autoimmune diseases are Sjogren's syndrome (SS, 2 cases), rheumatoid arthritis (RA, 2 cases), ulcerative colitis (UC, 1 case) and Crohn's disease (CD, 1 case). The NHL diseases located not only in the lymph node (n = 3) but also in extranodal sites (n = 3). Histologically, 3 cases were diffuse large B cell lymphoma (DLBCL), 2 cases were extranodal nasal NK/T lymphoma (ENKL) and 1 case was peripheral T cell lymphoma, not otherwise specified. Based on CD10, Bcl-6 and MUM1 expression patterns, all 3 DLBCL were classified as non-GC subtype. EBER positive tumor cells were detected in 2 case of ENKL. 5 patients achieved a complete remission (83%) and 1 patient was primary drug-resistant after CHOP chemotherapy or involved radiotherapy. Median survival from the time of lymphoma diagnosis was 3 years. 1 patient showed clinical improvement of the SS symptoms, 2 patients (CD and UC) showed stable state of disease and 2 patients with RA and 1 patient with SS needed continuing treatment for their autoimmune diseases after chemotherapy for NHL. It is concluded that the development of NHL is one of the most serious complications in patients with autoimmune diseases. There is an increased frequency of non-GC subtype DLBCL. CHOP combined with or without radiotherapy proves to be effective for autoimmune disease patients with aggressive NHL but ineffective for concurrent autoimmune diseases.
